The relationship between clozapine plasma levels and clinical response

Psychiatric Annals

Volumn 26, Issue 7, 1996, Pages 406-412

  Lindenmayer, Jean Pierre ^a,b   Apergi, Fotini Sonia ^b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MANHATTAN PSYCHIATRIC CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0030509910     PISSN: 00485713     EISSN: None     Source Type: Journal    
DOI: 10.3928/0048-5713-19960701-10     Document Type: Article

References (17)

1. Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988; 45:789-796.
2. Meltzer HY. Duration of clozapine trial in neuroleptic-resistant schizophrenia. Arch Gen Psychiatry. 1989; 46:672.
3. Klein HE, Ruther E, Ackenheil M, et al. Plasma levels vs clinical and biochemical effects of thioridazine, clozapine, benperidol, and penfluridol in acutely schizophrenic patients. In: Usdin E, Eckert H, Forrest IS, eds. Phenothiazines and Structurally Related Drugs: Basic and Clinical Studies. New York, NY: Elsevier/North-Holland; 1980.
4. Pirmohamed M, Williams D, Madden S, Templeton E, Park BK. Metabolism and bioactivation of clozapine by human liver in vitro. J Pharmacol Exp Ther. 1995; 272:984-990.
5. Thorup M, Fog R. Clozapine treatment of schizophrenic patients. Plasma concentration and coagulation factors. Acta Psychiatr Scand. 1977; 55:123-126.
6. Ackenheil VM, Brau H, Burkhart A, Franke A, Pacha W. Antipsychotic efficacy in relation to plasma levels of clozapine [in German; English abstract]. Arzneimittel-Forschung. 1976; 26:1156-1158.
7. Brau H, Burkhart A, Pacha W, Ackenheil M. Relationships between effects and plasma levels of clozapine [in German; English abstract]. Arzeimittel-Forschung. 1978; 28:1300.
8. Haring C, Fleischhacker WW, Schett P, Humpel C, Barnas C, Saria A. Influence of patient-related variables on clozapine plasma levels. Am J Psychiatry. 1990; 147:1471-1475.
9. Perry JP, Miller DD, Arndt SV, Cadoret RJ. Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients. Am J Psychiatry. 1991; 148:231-235.
10. Owen JA, Delva NJ, Lawson JS. Clozapine concentrations and clinical response in schizophrenic patients [letter; comment]. Am J Psychiatry. 1992; 149:1120-1121.
11. Hasegawa M, Guterrez-Esteinou R, Way L, Meltzer Y. Relationship between clinical efficacy and clozapine concentrations in plasma in schizophrenia: effect of smoking. J Clin Psychopharmacol. 1993; 13:383-390.
12. Piscitelli SC, Frazier JA, McKenna K, et al. Plasma clozapine and haloperidol concentrations in adolescents with childhood-onset schizophrenia: association with response. J Clin Psychiatry. 1994; 55(suppl B):94-97.
13. Potkin SG, Bera R, Gulasekaram B, et al. Plasma concentrations predict clinical response in treatment-resistant schizophrenia. J Clin Psychiatry. 1994; 55:133-136.
14. Lieberman JA, Kane JM, Safferman AZ, et al. Predictors of response to clozapine. J Clin Psychiatry. 1994; 55:126-128.
15. Miller DD, Fleming F, Holman T, Perry PJ. Plasma clozapine concentrations as a predictor of clinical response: a follow-up study. J Clin Psychiatry. 1994; 55(suppl B):117-121.
16. Kronig MH, Munne RA, Szymanski S, et al. Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients. Am J Psychiatry. 1995; 152:179-182.
17. McEvoy JP, VanderZwaag M, McGee M, Freudenreich O, Wilson WH, Cooper T. A double-blind randomized trial comparing clozapine treatment within three distinct serum level ranges in patients with refractory schizophrenia. (Abstract) Winter schizophrenia meeting; Crans, Switzerland; March 1996.